AI Article Synopsis

  • Moyamoya is a rare brain artery disease that causes strokes and TIAs in children, either on its own (MMD) or alongside other conditions (MMS), accounting for 6-10% of these incidents.
  • The study was conducted on 65 pediatric patients in Italy to analyze how the disease presents, progresses, is treated, and its outcomes.
  • Findings revealed that most patients had symptoms (82%), many experienced strokes or TIAs, and 73% underwent surgery; however, 20% had subsequent strokes, and at follow-up, 43% had motor deficits, 31% intellectual disabilities, and other complications.

Article Abstract

Background: Moyamoya is a rare progressive cerebral arteriopathy, occurring as an isolated phenomenon (moyamoya disease, MMD) or associated with other conditions (moyamoya syndrome, MMS), responsible for 6-10% of all childhood strokes and transient ischemic attacks (TIAs).

Methods: We conducted a retrospective multicenter study on pediatric-onset MMD/MMS in Italy in order to characterize disease presentation, course, management, neuroradiology, and outcome in a European country.

Results: A total of 65 patients (34/65 women) with MMD (27/65) or MMS (38/65) were included. About 18% (12/65) of patients were asymptomatic and diagnosed incidentally during investigations performed for an underlying condition (incMMS), whereas 82% (53/65) of patients with MMD or MMS were diagnosed due to the presence of neurological symptoms (symptMMD/MMS). Of these latter, before diagnosis, 66% (43/65) of patients suffered from cerebrovascular events with or without other manifestations (ischemic stroke 42%, 27/65; TIA 32%, 21/65; and no hemorrhagic strokes), 18% (12/65) of them reported headache (in 4/12 headache was not associated with any other manifestation), and 26% (17/65) of them experienced multiple phenotypes (≥2 among: stroke/TIA/seizures/headache/others). Neuroradiology disclosed ≥1 ischemic lesion in 67% (39/58) of patients and posterior circulation involvement in 51% (30/58) of them. About 73% (47/64) of patients underwent surgery, and 69% (45/65) of them received aspirin, but after diagnosis, further stroke events occurred in 20% (12/61) of them, including operated patients (11%, 5/47). Between symptom onset and last follow-up, the overall patient/year incidence of stroke was 10.26% (IC 95% 7.58-13.88%). At last follow-up (median 4 years after diagnosis, range 0.5-15), 43% (26/61) of patients had motor deficits, 31% (19/61) of them had intellectual disability, 13% (8/61) of them had epilepsy, 11% (7/61) of them had behavioral problems, and 25% (13/52) of them had mRS > 2. The proportion of final mRS > 2 was significantly higher in patients with symptMMD/MMS than in patients with incMMS ( = 0.021). Onset age <4 years and stroke before diagnosis were significantly associated with increased risk of intellectual disability ( = 0.0010 and = 0.0071, respectively) and mRS > 2 at follow-up ( = 0.0106 and = 0.0009, respectively).

Conclusions: Moyamoya is a severe condition that may affect young children and frequently cause cerebrovascular events throughout the disease course, but may also manifest with multiple and non-cerebrovascular clinical phenotypes including headache (isolated or associated with other manifestations), seizures, and movement disorder. Younger onset age and stroke before diagnosis may associate with increased risk of worse outcome (final mRS > 2).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120837PMC
http://dx.doi.org/10.3389/fped.2022.892445DOI Listing

Publication Analysis

Top Keywords

patients
10
moyamoya disease
8
18% 12/65
8
cerebrovascular events
8
onset age
8
pediatric moyamoya
4
disease
4
disease syndrome
4
syndrome italy
4
italy multicenter
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!